Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5776
Bio-Rad Laboratories Class B
BIO.B
$9.74B
| $214K | ﹤0.01% |
712
| – | – |
2019 Q2
28 quarters
|
|
5777
Vivid Seats
SEAT
$32.3M
| $214K | ﹤0.01% |
32,837
-2,255
| -6% | -$17.3K |
2021 Q4
18 quarters
|
|
5778
Strategy Shares Nasdaq 7HANDL Index ETF
HNDL
$622M
| $214K | ﹤0.01% |
9,360
-722
| -7% | -$16.3K |
2021 Q2
20 quarters
|
|
5779
Flanigan's Enterprises
BDL
$90.8M
| $214K | ﹤0.01% |
4,762
+1
| +0% | +$34 |
2016 Q3
39 quarters
|
|
5780
Caribou Biosciences
CRBU
$49.5M
| $214K | ﹤0.01% |
121,320
-123,792
| -51% | -$245K |
2021 Q3
19 quarters
|
|
5781
Goldman Sachs Future Tech Leaders Equity ETF
GTEK
$235M
| $213K | ﹤0.01% |
3,393
+1,643
| +94% | +$88.9K |
2021 Q3
19 quarters
|
|
5782
AB US Large Cap Strategic Equities ETF
LRGC
$1.36B
| $213K | ﹤0.01% |
2,548
| – | – |
2025 Q3
3 quarters
|
|
5783
VictoryShares US Small Cap High Div Volatility Wtd ETF
CSB
$236M
| $213K | ﹤0.01% |
3,240
-2,388
| -42% | -$153K |
2020 Q3
23 quarters
|
|
5784
Opendoor Technologies Inc Series Z Warrants
OPENZ
$1.87M
| $212K | ﹤0.01% |
883,690
-57,960
| -6% | -$16.6K |
2025 Q4
2 quarters
|
|
5785
Direxion Daily MSCI Brazil Bull 2X ETF
BRZU
$150M
| $212K | ﹤0.01% |
2,378
-33
| -1% | -$3.47K |
2024 Q2
8 quarters
|
|
5786
Health Catalyst
HCAT
$131M
| $211K | ﹤0.01% |
106,127
-28,053
| -21% | -$40.5K |
2019 Q3
27 quarters
|
|
5787
Definitive Healthcare
DH
$105M
| $211K | ﹤0.01% |
254,149
-170,152
| -40% | -$156K |
2021 Q3
19 quarters
|
|
5788
FTC Solar
FTCI
$27.8M
| $211K | ﹤0.01% |
41,460
+25,675
| +163% | +$119K |
2021 Q2
20 quarters
|
|
5789
YieldMax MSTR Option Income Strategy ETF
MSTY
$1.02B
| $210K | ﹤0.01% |
17,172
-50
| -0.3% | -$1.07K |
2024 Q3
7 quarters
|
|
5790
Insight Molecular Diagnostics
IMDX
$91.3M
| $210K | ﹤0.01% |
35,515
-573
| -2% | -$2.83K |
2016 Q1
41 quarters
|
|
5791
JPMorgan New York Tax Free Bond ETF
JTNY
$434M
| $209K | ﹤0.01% |
+4,172
| New | +$210K |
2026 Q2
0 quarters
|
|
5792
John Hancock Disciplined Value International Select ETF
JDVI
$783M
| $209K | ﹤0.01% |
+5,427
| New | +$209K |
2026 Q2
0 quarters
|
|
5793
Oramed Pharmaceuticals
ORMP
$172M
| $209K | ﹤0.01% |
43,357
+29,305
| +209% | +$117K |
2013 Q4
50 quarters
|
|
5794
Frontier Nuclear and Minerals Inc
FNUC
$34.1M
| $207K | ﹤0.01% |
135,319
-341,385
| -72% | -$747K |
2022 Q1
17 quarters
|
|
5795
Yorkville Acquisition Corp Unit
MCGAU
| $206K | ﹤0.01% |
20,000
| – | – |
2025 Q2
4 quarters
|
|
5796
AMTD IDEA Group
AMTD
$46M
| $205K | ﹤0.01% |
212,867
| – | – |
2023 Q1
13 quarters
|
|
5797
Palmer Square Capital BDC
PSBD
$292M
| $205K | ﹤0.01% |
19,639
-51,705
| -72% | -$552K |
2024 Q1
9 quarters
|
|
5798
Panagram AAA CLO ETF
CLOX
$337M
| $204K | ﹤0.01% |
7,945
+6,380
| +408% | +$163K |
2026 Q1
1 quarter
|
|
5799
Vanguard Core Bond ETF
VCRB
$7.6B
| $203K | ﹤0.01% |
2,634
-2,059
| -44% | -$159K |
2025 Q2
4 quarters
|
|
5800
DELISTED
Emerald Holding
EEX
| $203K | ﹤0.01% |
40,327
-11,462
| -22% | -$55.7K |
2017 Q2
36 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.